gemcitabine has been researched along with pm 01183 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Álamo, P; Allavena, P; Avilés, P; Céspedes, MV; Cuevas, C; Gallardo, A; Galmarini, CM; Guillén, MJ; Hidalgo, M; López-Casas, PP; Mangues, R; Sarno, F | 1 |
| Chen, T; Choy, E; Cote, GM; Demetri, G; George, S; Marino-Enriquez, A; Merriam, P; Morgan, J; Nathenson, MJ; Thornton, K; Wagner, AJ | 1 |
1 trial(s) available for gemcitabine and pm 01183
| Article | Year |
|---|---|
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbolines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Research Design; Sarcoma | 2020 |
1 other study(ies) available for gemcitabine and pm 01183
| Article | Year |
|---|---|
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Topics: Adenocarcinoma; Animals; Apoptosis; Carbolines; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; DNA Damage; Down-Regulation; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Macrophages; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |